Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Articles online first > Minerva Pediatrica 2020 Dec 11

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Pediatrica 2020 Dec 11

DOI: 10.23736/S0026-4946.20.06140-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Insights on Kawasaki disease and multisystem inflammatory syndrome; relationship with COVID-19 infection

Giuseppe CALCATERRA 1, Jawahar L. MEHTA 2, Vassilios FANOS 3, Pier Paolo BASSAREO 4

1 Post graduate medical School, University of Palermo, Palermo, Italy; 2 Division of Cardiology, University of Arkansas for Medical Sciences and the VA Medical Center, Little Rock, AR, USA; 3 Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria, University of Cagliari, Monserrato, Cagliari, Italy; 4 University College of Dublin, Mater Misericordiae University Hospital, Dublin, Republic of Ireland


PDF


At the beginning of coronavirus disease 2019 (COVID-19) children seemed to be less affected and with milder symptoms than adults. Afterward, however, a warning was released regarding the possible association between COVID-19 and Kawasaki disease (KD) or Kawasaki-like disease. Thereafter, labels of Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) in Europe and Multisystem Inflammatory Syndrome in Children (MIS-C) in the USA were coined to refer to this new disease entity. The reality is that PIMS-TS/MIS-C resembles certain KD complications such as toxic shock syndrome and macrophage activation syndrome than to classic KD. PIMS-TS/MIS-C and KD share the viral origin (however just supposed for KD) and consequent dysregulated innate immune system inflammatory reaction. PIMS-TS/MISC symptoms occur about 2-4 weeks after the onset of COVID-19 or having been exposed to somebody positive for COVID-19, rather than in the acute phase of the infection. Clinically PIMS-TS/MIS-C affects older children than KD and presents more often with gastrointestinal symptoms, shock, and multi-organ dysfunction. myocarditis is more common in PIMS-TS/MIS-C than coronary artery aneurysms formation seen in KD. There are also differences in laboratory tests and immunology responses in KD and PIMS-TS/MIS-C. Thus PIMS-TS/MIS-C seems to be a new and multifaceted entity, distinct from KD, notwithstanding some common features in both. The dysregulated innate immune system reaction is responsible for PIMS-TS/MIS-C onset and outcome. A multidisciplinary approach, involving paediatric intensivists, paediatric cardiologists, infectious disease specialists, immunologists, and rheumatologists, is needed for the treatment of these children.


KEY WORDS: COVID-19; SARS-CoV-2; Kawasaki disease; PIMS-TS; MIS-C; Innate immune system

inizio pagina